A Phase I Bioequivalence Study To Compare The Plasma Pharmacokinetics Of Five 1-mg And One 5-mg AG-013736 Tablets In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Axitinib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Nov 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 17 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 11 Nov 2009 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.